Skip to content

menu

Pharma in Brief logo
HomeAboutContact
Search
Close
Pharmaceuticals and life sciencesIntellectual propertyLife sciences and healthcare
View topics Archives
Subscribe

Pharma in Brief

CDA-AMC

Subscribe to CDA-AMC via RSS

National Pharmacare: Canada’s Drug Agency Consulting on National Bulk Purchasing Strategy

Photo of Sarah PenningtonPhoto of Paul JorgensenPhoto of Kristin Wall
By Sarah Pennington, Paul Jorgensen & Kristin Wall on July 14, 2025

Canada’s Drug Agency/L’Agence des médicaments du Canada (CDA-AMC) has launched a consultation on advice for a national bulk purchasing strategy for prescription drugs and related products. Notably, the advice proposes making the pan-Canadian Pharmaceutical Alliance (pCPA)…

National Pharmacare: Canada’s Drug Agency Consulting on List of Essential Prescription Drugs

Photo of Sarah PenningtonPhoto of Paul JorgensenPhoto of Kristin Wall
By Sarah Pennington, Paul Jorgensen & Kristin Wall on June 24, 2025

On June 19, 2025, Canada’s Drug Agency/L’Agence des médicaments du Canada (CDA-AMC) announced a consultation on a proposed list of essential prescription drugs and related products intended to inform the development of a national formulary. The consultation is…

Subscribe to Pharma in Brief

Subscribe to this publication

British Columbia becomes second province to sign pharmacare agreement

Photo of Sarah PenningtonPhoto of Paul JorgensenPhoto of Kristin Wall
By Sarah Pennington, Paul Jorgensen & Kristin Wall on March 7, 2025

On March 6, 2025, British Columbia became the second province to announce the signing of a pharmacare agreement with Canada’s federal government. Manitoba was the first province to do so, on February 27, 2025 (our report here).

British Columbia’s

…

Pharma in Brief

LinkedIn Twitter Facebook RSS YouTube
Published by
Norton Rose Fulbright LLP logo
DisclaimerPrivacy policy

About

Stay up-to-date with legal and regulatory developments affecting the pharmaceutical industry. Pharma in Brief provides timely updates with a focus on the key take-away you need to know.

Read more

Topics

Archives

Copyright © 2025, Norton Rose Fulbright LLP. All rights reserved.